New drug combo aims to keep lung cancer at bay
NCT ID NCT07640789
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a new drug (BL-B01D1) to the standard pill osimertinib can help people with a certain type of Stage III lung cancer stay cancer-free longer. Participants must have an EGFR gene mutation and have already completed chemotherapy and radiation without their cancer growing. The trial will compare the combination against osimertinib alone in about 418 adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Step counts may predict trouble during lung cancer therapy
- New pill targets Hard-to-Treat lung cancer in patients who Can't have standard therapy
- New drug cocktail aims to shrink inoperable lung tumors enough for surgery
- New combo therapy aims to stop lung cancer from returning
- Blood test guides new attack on lung cancer return
- Real-World study tracks immune response in lung cancer patients after standard treatment